Penn Medicine researchers are now able to identify cancerous tumours of the lung using infrared imaging that makes hidden tumours glow during surgery. In a pilot study, researchers performed the first in-human demonstration of this technology to identify lung tumours during surgery without prior knowledge of their location or existence.
Lung cancer is one of the deadliest of cancers, with more than 250,000 newly diagnosed cases in the United States each year. Approximately 80,000 patients with non-small cell lung cancer (also known as adenocarcinoma) undergo thoracic surgery each year to remove their nodule. Ten to 15 percent often have additional nodules that are unable to be seen on preoperative imaging or identified by the surgeon, visually or by finger palpation during surgery. New findings suggest that infrared technology, or near infrared imaging (NIR), has the ability to identify these tumours and save many of these patients from a cancer recurrence.
The Penn team tested the technology on 18 patients between the ages of 29 to 78 from January to July 2012 with a diagnosis of a single pulmonary nodule. Each patient was injected with an FDA-approved dye, indocyanine green, 24 hours before surgery.
The properties of the dye allow it to bind with receptors on cancerous tumours, causing them to fluoresce neon green under infrared light. During surgery, an infrared camera was placed above the chest to search for any fluorescing tumours. In this study, the camera correctly located 16 of the 18 primary tumours (91 percent).
The rest of the lung was then imaged and five additional nodules were identified that could not otherwise be seen or felt by the surgeon. Two of the five were located in the same lobe of the lung as the primary nodule and three were located in other lobes. All five additional nodules were removed.
The team state that NIR imaging has not been used in thoracic surgery to identify pulmonary nodules that have not been diagnosed preoperatively. The team have previously showed the technology to be successful in identifying unknown tumours in dogs.
By removing these pulmonary nodules in the current human trials the researchers state that they were able to prevent a local cancer recurrence and also reduced these patients’ chances of their cancer spreading and developing into metastatic disease.
The team also examined the two tumours that did not fluoresce and found that the non-fluorescing nodules were deeper in the lung than those that fluoresced. The team pinpointed the size that tumors needed to be in order to be detected by this technology, and suggested that those buried too deep within the lung tissue would go undetected.
This technology eliminates any second-guessing by the surgeon, is safe, it gives off less energy than the lights in the operating room; and it is easy-to-understand, offering essential information to the surgeon in real-time, giving it the ability to make a real difference for patients.
Next, the team plans to apply this technology in a minimally-invasive setting and expand into other cancer types such as breast and renal cancer with the aim of identifying deeper nodules that are difficult to locate since they cannot be felt by the surgeon.
Michelle is a health industry veteran who taught and worked in the field before training as a science journalist.
Featured by numerous prestigious brands and publishers, she specializes in clinical trial innovation--expertise she gained while working in multiple positions within the private sector, the NHS, and Oxford University.